Within a cellular clinical viewpoint, Relafen 750 (Naproxen) exhibits particular properties . It operates primarily as a cyclooxygenase agent, preferentially blocking cyclooxygenase-2 (COX-2), an protein implicated in prostaglandin synthesis . This targeted inhibition results in diminished inflammation and pain , delivering potential benefits for i